Fundraising FoxVenrock Healthcare Capital Partners — Full Portfolio
18 tracked investments · listed companies and verified rows first
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyRA CapitalWellington ManagementBlackstone Life SciencesPerceptive Xontogeny VentureRTW Investments L.P.
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsOrbiMed+2 more
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+5 more
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsAvoro Capital AdvisorsFrazier Life Sciences5AM VenturesSamsara BioCapitalVivo Capital
Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.
BiotechHealthtechNew York, US
Shoshana Shendelman(Executive Officer, Director)in
BoardLes Funtleyder(Director)
Co-investorsEvolution VC PartnersAlexandria
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesLifeSci Venture PartnersSofinnova VenturesThe W FundViking GlobalCommodore Capital+6 more
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo Capital+1 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsLifeSci Venture PartnersBain Capital Life SciencesCasdin Capital
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalNextech InvestViking GlobalJanus Henderson InvestorsRA CapitalViking Global Investors
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund+5 more
Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.
Cloud ComputingEnterprise SoftwareFintechSaaS
Co-investorsCore Venture CapitalNycaNyca PartnersARCH Venture PartnersFidelity InvestmentsInvus+3 more
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)
Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedSanofi VenturesInvusPoint72
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Concentric AnalgesicsCorvidia TherapeuticsLusaris Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.